(PharmaNewsWire.Com, September 29, 2017 ) Malignant pleural mesothelioma is a rare cancer often diagnosed in people who have been exposed to high levels of asbestos. The malignancy affects the pleura, a thin membrane of lubricating cells that lines the lungs and chest wall. Peritoneal mesothelioma originates in the abdomen and as a result, symptoms often include abdominal pain, weight loss, nausea, and vomiting. Other symptoms include anemia, bowel obstructions, chest pain and hemoptysis.
Report Highlights
Publisher's Pharmaceutical and Healthcare latest pipeline guide Malignant Mesothelioma-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Malignant Mesothelioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Malignant Mesothelioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Malignant Mesothelioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 4, 34, 25, 15, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 3, 6 and 6 molecules, respectively.
Malignant Mesothelioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Table of Contents Table of Contents 2 Introduction 5 Malignant Mesothelioma-Overview 6 Malignant Mesothelioma-Therapeutics Development 7 Malignant Mesothelioma-Therapeutics Assessment 20 Malignant Mesothelioma-Companies Involved in Therapeutics Development 33 Malignant Mesothelioma-Drug Profiles 60 Malignant Mesothelioma-Dormant Projects 521 Malignant Mesothelioma-Discontinued Products 523 Malignant Mesothelioma-Product Development Milestones 524 Appendix 536
List of Figures Number of Products under Development for Malignant Mesothelioma, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Number of Products by Top 10 Targets, H2 2017 Number of Products by Stage and Top 10 Targets, H2 2017 Number of Products by Top 10 Mechanism of Actions, H2 2017 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 Number of Products by Top 10 Routes of Administration, H2 2017 Number of Products by Stage and Top 10 Routes of Administration, H2 2017 Number of Products by Top 10 Molecule Types, H2 2017 Number of Products by Stage and Top 10 Molecule Types, H2 2017
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
